Management of CMV retinitis in the era of highly active antiretroviral therapy

International Journal of Antimicrobial Agents

Volumn 13, Issue 1, 1999, Pages 1-7

  Jouan, Marc ^a   Katlama, Christine ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

CMV; HIV; Retinitis; Therapy

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; CD4 ANTIGEN; CIDOFOVIR; FOSCARNET; GANCICLOVIR; PROBENECID; PROTEINASE INHIBITOR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; BLOOD TOXICITY; CYTOMEGALOVIRUS INFECTION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG RESISTANCE; EYE DISEASE; FEVER; GENITAL ULCER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYDRATION; HYPOCALCEMIA; IMPLANT; INTRAOCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; INTRAVITREAL DRUG ADMINISTRATION; IRIDOCYCLITIS; KIDNEY TUBULE NECROSIS; LONG TERM CARE; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OPPORTUNISTIC INFECTION; ORAL DRUG ADMINISTRATION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; RETINITIS; REVIEW; VIRUS LOAD; VOMITING;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS RETINITIS; HUMANS;

EID: 0032827913     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(99)00100-4     Document Type: Review

References (46)

1. Sepkowitz K.A. Effects of HAART on natural history of AIDS-related opportunistic disorders. Lancet. 351:1998;228-230.
2. Autran B., Carcelain G., Li T.S. et al. Positive effects of combined antiretroviral therapy on CD+T cell homeostasis and function in advanced HIV disease. Science. 277:1997;112-116.
3. Gallant J.E., Moore R.D., Richman D.D. et al. Clinical incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated zidovurine. The Zidovudine Epidemiology Study Group. J. Infect. Dis. 166:1992;1223-1227.
4. Peters B.S., Beck E.J., Anderson S. et al. Cytomegalovirus infection in AIDS patients. Patterns of disease, response to therapy and trends in survival. J. Infect. Dis. 23:1991;129-137.
5. Baril L, Jouan M, Caumes E, Mengual X, Bricaire F, Katlama C. The impact of highly active antiretroviral therapy on the incidence of CMV disease in AIDS patients. In: the Thirty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada, 1997 (abstract I-31).
6. Costagliola D, Salmon D, Michon C, Katlama C, Lang JM, Gerbe J. Recurrence of CMV disease in patients with a history of CMV retinitis receiving protease inhibitors (abstract 16/22239). In: The Twelfth World AIDS Conference. Geneva Switzerland, 1998.
7. Tanguilig G.G., Rutzen A.R., Ortega-Larrocea G. Regression of cytomegalovirus retinitis associated with protease-inhibitor treatment in patients with AIDS. Am. J. Ophthalmol. 125(4):1998;567-568.
8. Jacobson M.A., Zagans M., Pavan P.R. et al. Cytomegalovirus retinitis after initiation of highly active entiretroviral therapy. Lancet. 349:1997;1443-1445.
9. Gilquin J., Piketty C., Thomas V., Gonzales-Canali G., Belec L., Kazatchkine M.D. Acute cytomegalovirus infection in AIDS patients with CD4 counts above 100×106 cells/L following combination antiretroviral therapy including protease inhibitors. AIDS. 11:1997;1659-1660.
10. Bachman D.M., Bruni L.M., DiGoia R.A. Visual field tesing in the management of cytomegalovirus retinitis. Ophtalmology. 99:1992;1393-1399.
11. Palestine A.G., Polis M.A., DeSmet M.D. et al. A randomized, controlled study of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann. Intern. Med. 115:1991;665-673.
12. Roarty J.D., Fisher E.J., Nusbaum J.J. Long term visual morbidity of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. Ophtalmology. 1000:1993;1685-1688.
13. Shinkai M., Bozzette S.A., Powderly W., Frame P., Spector S.A. Utility of urine and leukocyte cultures and plasma DNA polymerase chain reaction for identification of AIDS patients at risk for developing human cytomegalovoirus disease. J. Infect. Dis. 175:1997;302-304.
14. Dodt K.K., Jacobsen P.H., Hofmann B. et al. Development of cytomegalovirus (CMV) disease may be predicted in HIV-infected patients by CMV polymerase chain reaction and the antigenemia test. AIDS. 11:1997;F21-F28.
15. Bowen E.F., Sabin C.A., Wilson P. et al. Cytomegalovirus (CMV) viraemia detected by polyperase chain reaction identifies a group of HIVpositive patients at high risk of CMV disease. AIDS. 11:1997;889-893.
16. Oberg B. Antiviral effects of phosphonoformate (PFA, foscarnet sodium). Pharmacol. Ther. 40:1989;213-285.
17. Ganem D. Human herpes virus 8 and its role in the genesis of Kaposi's sarcoma. Curr. Clin. Top. Infect. Dis. 18:1998;237-251.
18. Jacobson M.A., Causey D., Polsky B., Hardy D., Chown M., Davis R. et al. A dose-ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus retinitis in AIDS. J. Infect. Dis. 168:1993;444-448.
19. Katlama C, Dohin E, Caumes E, et al. Foscarnet induction therapy for cytomegalovirus retinitis in AIDS-comparison of twice-daily and three-daily regimens. J AIDS 1992;5 (Suppl):S18-S24.
20. Deray G., Martinez F., Katlama C., Levaltier B., Beaufils H., Danis M. et al. Foscarnet nephrotoxicity: mechanism, incidence and prevention. Am. J. Nephrol. 9:1989;316-321.
21. Benson P, Nahass R, Deresinski S, et al. Safety of oral versus. intravenous hydratation during induction therapy with intravenous foscavir (TM) in AIDS patients with CMV infections. 1997. In: The Fourth Conference on Retroviruses and Opportunistic Infections. Washington, 22-26 January [abstract 299-S31].
22. Studies of Ocular Complications of AIDS Research Group in collaboration with AIDS clinical Trials Group. Mortality in patients acquired immumnodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med 1992;326:213-220.
23. Douglas AJ. Incidence of resistant cytomegalovirus in patients being treated for CMV retinitis. In: The Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1-5, 1998 [abstract 262].
24. Kaiser L., Perrin L., Hirshel B., Furrer H. et al. Foscarnet decreases human immunodeficiency virus RNA. J. Infect. Dis. 172:1995;225-227.
25. Jacobson M.A. Treatment of cytomegalovirus retinitis in patients with the acquired immunodifiency syndrome. N. Eng. J. Med. 337:1997;105-114.
26. Drew W.L., Ives D., Lalezari J.P., Crumpacker C., Follansbee S.E., Benson C.A. et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. N. Engl. J. Med. 333:1995;615-620.
27. Oral Ganciclovir European and Australian Cooperative Study Group. Intravenous versus oral ganciclovir European/Australian cooperative study of efficacy and safety in the prevention of cytomegalovirus retinitis recurrence in patients with AIDS. AIDS 1995;9:471-477.
28. Guembel H, KriegsteinerS, Rosenkranz C, Koch FHJ, Ohrloff C. Rhegmatogenous retinal detachment associated with the ganciclovr implant in patients with AIDS and CMV-retinitis. In: The Twelfth World AIDS Conference. Geneva, 1998 [abstract 32237].
29. Stanat S.C., Reardon J.E., Erice J.A. et al. Severe resistant cytomegalovirus clinical isolates. Mode of resistance to ganciclovir. Antimicrob. Agents Chemother. 35:1991;2191-2197.
30. Drew W.L., Miner R.C., Bisch D.F., Follansbee S.E., Gullett J. et al. Prevalence of resistance in patients receiving gangiclovir for serious cytomegalovirus infection. J. Infect. Dis. 163:1991;716-719.
31. Cihlar T., Fuller M.D., Mulato A.S., Cherrington J.M. A point mutation in human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture. Virology. 248(2):1998;382-393.
32. Lalezari J.P., Stagg R.J., Kupperman B.D., Holland G.N., Kremer F. et al. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. Ann. Intern. Med. 126:1997;257-263.
33. Safrin S., Cherrington J., Jaffe H.S. Clinical uses of cidofovir. Rev. Med. Virol. 7:1997;145-156.
34. Cherrington JM, Fuller MF, Lalezari JP, Miner R, Chen MS, Drew WL. In vitro antiviral susceptibilities of isolates from CMV retinitis patients receiving first or second line cidofovir therapy. In: Abstract of the Fourth Conference on Retroviruses and Opportunistic Infections. Washington, 22-26 January, 1997 [abstract 120].
35. Studies of Ocular Complications of AIDS Research Group, AIDS Clinical Group. Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. Arch. Ophtalmol. 1996;114:23-32.
36. Cochereau-Massin I., Lehoang P., Lautier-frau M. et al. Efficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophtalmology. 98:1991;1348-1353.
37. Martin D.F., Park D.J., Mellow S.D., Ferris F.L. et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. Arch. Ophtalmol. 112:1994;1531-1539.
38. The Chiron Ganciclovir Implant Study Group. A randomized controlled multicenter clinical trial of a sustained-released intraocular ganciclovir implant in AIDS patients with CMV retinitis. In: The Thirty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, 1995 [abstract 215].
39. Jacobson M.A., Wulfsohn M., Feinberg J.E. et al. Phase II dose-ranging trial of foscarnet salvage therapy for cytomegalovirus retinitis in AIDS patients intolerant of or resistant to ganciclovir (ACTG protocol 093). AIDS. 8:1994;451-459.
40. Macdonald J.C., Torriani F.J., Morse L.S., Karavellas M.P., Reed J.B., Freeman W.R. Lack of relapse of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevation in CD4 T cells in response to highly active antiretroviral therapy. J. Infect. Dis. 177:1998;1182-1187.
41. Tural C., Romeu J., Sirera G. et al. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients. J. Infect. Dis. 177:1998;1080-1083.
42. Torriani F, Freeman W, Durand D, Karavellas M,Schrier. Evidence that HAART induced immune recovery vitritis in CMV retinitis patients is immune mediated. In: The Twelfth World AIDS Conference. Geneva 1998 [abstract 15/22240].
43. Spector S.A., McKinley G.F., Lalezari J.P., Samo T. et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. N. Engl. J. Med. 334:1996;1491-1497.
44. Brosgart C.L., Louis T.A., Hillman D.W., Craig C. et al. A randomized, placebo-controlled trial of the safety and efficacy of oral gangiclovir for the prophylaxis of cytomegalovirus and disease in HIV infected individuals. AIDS. 12(3):1998;269-277.
45. Spector S.A., Wong R., Hsia K., Filcher M., Stempien M.J. Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients. J. Clin. Invest. 101:1998;497-502.
46. Feindberg J.E., Hurwitz S., Cooper D. et al. A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. J. Infect. Dis. 177:1998;48-56.